Stefan Müllner, PhD – the long time CEO of the autoimmune diagnostic specialist Protagen AG, Dortmund, Germany, with strong industrial background from management and board positions in the pharma (Hoechst, Aventis), biotech (Maltagen, Phenion, BiotEx, SusTech) consumer products (Henkel) and venture capital industries (fundamenta Capital) and has joined the Advisory Board of SensDx SA.
With his knowledge and experience, Stefan will support the company in the field of validation and further development of the diagnostic technology of the devices as well as sales and entry strategies of the SensDx diagnostic test into the German market. Attendance at the Advisory Board of Dr Müllner will also be involved in minimizing the risk of commercialization of SensDx technology through the use of a synergistic industrial experience.
– To succeed in Germany, we must become recognizable there. We need to build a strong brand – says Tomasz Gondek, President of the Board of SensDx SA. – Stefan will be an important help for us. As renowned expert in the the Biotech and Diagnostic industry, he will help us identify the right market segment and address the implementation of our activities based on reliable business analysis and technology assessment. This is the last straight before selling in Germany.
– I strongly believe in SensDx. It’s a team of great, young, passionate people. They have excellent, flexible technology – complements Stefan Müllner, PhD. – I am excited to to cooperate and help to provide them the access to my dedicated network of contacts and experiences in all important areas of the natural sciences.
Stefan will join Alex Klarmann in the SensDx SA Advisory Board, who is a team leading specialists, to support the management team of SensDx not only with their competence aand network, but also with expert consulting.
Dr. Stefan Müllner studied at Frankfurt/M. University, and holds a Diploma in Chemistry and Ph.D. in Biochemistry. After his postdoc in the US he started his industrial career at Hoechst Pharma and Corporate Research. Then he moved to Henkel as VP Enzyme Technology. After spending three years in the Venture Capital industry, he joined the management board of Protagen where he served as CEO until 2016. Stefan developed highly specialized biotech service businesses to global technology leadership, and now supports technology companies and investors to identify the most attractive products and service businesses for a successful business strategy.